This finding is in accordance with that found in the retrospective review performed by Sokumbi et al. [3] at the Mayo Clinic in Rochester, Minnesota, which reported a mean duration of 34.5 months between the initiation of anti-TNF therapy and the development of vasculitis. The gene discussed is TNF; the disease is vasculitis.